We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.56 | 1.91% | 29.82 | 29.81 | 29.83 | 30.08 | 29.715 | 30.04 | 4,236,458 | 18:13:02 |
From May 2019 to May 2024
By Stephen Nakrosis
The U.S. Food and Drug Administration on Friday said it gave approval to Genentech Inc.'s Evrysdi as a treatment for spinal muscular atrophy.
The FDA said Evrysdi, or risdiplam, was approved to "treat patients two months of age and older with spinal muscular atrophy, a rare and often fatal genetic disease affecting muscle strength and movement," and added, "This is the second drug and the first oral drug approved to treat this disease."
The FDA also said "The efficacy of Evrysdi for the treatment of patients with infantile-onset and later-onset SMA was evaluated in two clinical studies."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
August 07, 2020 15:02 ET (19:02 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
